Australia markets open in 3 hours 33 minutes

Pharmaxis Ltd (PMXSF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0650-0.0134 (-17.09%)
As of 10:56AM EDT. Market open.

Pharmaxis Ltd

20 Rodborough Road
Frenchs Forest, NSW 2086
Australia
61 2 9454 7200
http://www.pharmaxis.com.au

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees63

Key executives

NameTitlePayExercisedYear born
Mr. Gary Jonathan Phillips BPharm, MBACEO, MD & Director468.13kN/A1961
Dr. Brett Charlton MBBS Ph.D., Ph.D.Co-Founder & Medical Director371.57kN/A1956
Mr. David Morris McGarvey BA, CA, CPACFO & Company Sec.374.6kN/A1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D.Head of Drug Discovery365.48kN/A1964
Ms. Kristen Morgan B.Sc., BSc, PGDipBusAdmin, MMedScAlliance Management - Head of Medical & Regulatory Affairs234.91kN/A1972
Mr. Cameron David BillingsleyGen. CounselN/AN/A1977
Dr. Dieter HamprechtHead of Chemistry for Drug DiscoveryN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting myelofibrosis and other cancers, and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Corporate governance

Pharmaxis Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.